This suggests that KRAS and GNAS mutations in liquid biopsy samples from IPMN patients could primarily serve to reinforce the decision for conservative surveillance in cases of branch duct IPMN without worrisome features—which underlines the study's clinical relevance, providing a more transparent basis for risk stratification and management decisions. Here, KRAS is linked to pancreatic intraductal papillary-mucinous neoplasm.